Press release
Bipolar Disorder Therapeutics Market is Projected to Grow at a 3.4% CAGR, Reaching US$ 10,970 Million by 2035 | Fact.MR Report
Bipolar Disorder Therapeutics Market
Pharmaceutical innovation is slowly transforming the therapeutic terrain. While atypical antipsychotics and mood stabilizers are still the pillars of treatment, other emerging classes like glutamate modulators and digital therapeutics are picking up pace. New treatments demonstrate a higher trend towards precision psychiatry, whereby treatments are increasingly being adapted to a patient's genetic, metabolic, and behavioral makeup.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7280
Country-wise Analysis
The U.S. market for bipolar disorder therapeutics will register 5.9% CAGR during the forecast period. Increasing prevalence of bipolar disorder, coupled with rising awareness regarding mental well-being, is fundamentally dominating the therapeutic landscape in the nation. Expanding healthcare infrastructure, universal access to mental health care, and strong insurance coverage support systems are stimulating treatment penetration.
UK bipolar disorder therapeutics market is expected to grow at a 5.2% CAGR during the forecast period. Advances in mental health infrastructure and growing public awareness are the most important drivers that support growth across the country. The National Health Service (NHS) initiatives towards integrating mental health services into primary care are enhancing early diagnosis and treatment rates for bipolar disorder. Investment in research to identify genetic and biomarker-based therapeutic targets is fueling the creation of personalized treatment approaches.
The French market for bipolar disorder therapeutics will increase at a 5.0% CAGR during the study period. Rising mental health awareness and government initiatives for improved psychiatric treatment are fueling growth across France. Enhanced access to mental health services in the public healthcare system is encouraging earlier diagnosis and treatment initiation. Growing research into new pharmacological treatments, including next-generation antipsychotics with better safety profiles, is fueling product development.
Segment-wise Analysis
By Type
The Bipolar Disorder Therapeutics Market, according to type, is dominated by antipsychotic drugs in combination with mood stabilizers, with antipsychotic drugs projected to hold 35% industry share, followed by mood stabilizers at 30%.
By End-use
The bipolar disorder therapeutics market, based on end-use, is divided into hospitals, which comprise 50%, followed by outpatient clinics at 25%.
Competitive Outlook
The market of bipolar disorder therapeutics consists of large multinational drug firms involved in all the major psychiatric drug classes. These firms are leveraging their worldwide presence, experience in conducting clinical trials, and R&D pipelines to gain established positions in established and emerging mental health markets. Greater competitive activity is currently being observed in the segments of second-generation antipsychotics, long-acting injectables, and more safer mood stabilizers.
Johnson & Johnson has continued to dominate through its Janssen unit with novel formulations of atypical antipsychotics, a few of them long-acting treatments focusing on adherence. Otsuka Pharmaceutical and Lundbeck A/S have maintained the momentum by creating differentiated products like brexpiprazole and aripiprazole LAI. AbbVie, following the acquisition of Allergan, is gaining by combining a bigger neuropsychiatric pipeline with more visibility; by contrast, Eli Lilly, Pfizer, and GlaxoSmithKline have legacy products that are facing intense pressure due to looming patent expirations and generic entry.
Browse Full Report: https://www.factmr.com/report/bipolar-disorder-therapeutics-market
Key Players
Bristol-Myers Squibb Company
Eli Lilly and Company
Astellas Pharma Inc.
Allergan plc (now AbbVie)
Johnson & Johnson (Janssen)
GlaxoSmithKline plc
AbbVie Inc.
Pfizer Inc.
Novartis International AG
Gedeon Richter Plc
Lundbeck A/S
Janssen Pharmaceutica N.V.
Otsuka America Pharmaceutical Inc.
Sumitomo Dainippon Pharma Co. Ltd.
Validus Pharmaceuticals LLC
Segmentation
By Type :
Antipsychotic Drugs
Anticonvulsants
Mood Stabilizers
Antidepressant Drugs
Anti-anxiety Drugs
By Mechanism of Action (MOA) :
Dopamine Antagonists
Serotonin Modulators
GABAergic Agents
Glutamate Receptor Antagonists
By Dosage Form :
Oral Medications
Injectables
Transdermal Patches
Intranasal Sprays
By End-Use :
Hospitals
Outpatient Clinics
Home Care
Pharmacies
Online Pharmacies
By Region :
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA (Middle East & Africa)
Check out More Related Studies Published by Fact.MR:
Radiation Proctitis Treatment Market
https://www.factmr.com/report/5281/radiation-proctitis-treatment-market
Endoscopy Operative Devices Market
https://www.factmr.com/report/endoscopy-operative-devices-market
Rhizoma Gastrodiae Tablets Market
https://www.factmr.com/report/rhizoma-gastrodiae-tablets-market
Optical Microscopes Market
https://www.factmr.com/report/optical-microscopes-market
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bipolar Disorder Therapeutics Market is Projected to Grow at a 3.4% CAGR, Reaching US$ 10,970 Million by 2035 | Fact.MR Report here
News-ID: 4025920 • Views: …
More Releases from Fact.MR
Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
The latest report on the Bioinformatics Market, projecting robust growth driven by the increasing demand for genomic research, advancements in artificial intelligence (AI), and the rising adoption of precision medicine. Valued at USD 14.29 billion in 2024, the global market is forecast to expand at a compound annual growth rate (CAGR) of 13.4%, reaching USD 50.25 billion by 2034. This significant growth underscores the critical role of bioinformatics in decoding…
Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Ke …
Fact.MR today released its latest report on the Residential Robotic Vacuum Cleaner Market, projecting robust growth driven by increasing demand for automation, busy lifestyles, and advancements in smart home technologies. Valued at USD 3.0 billion in 2023, the global market is forecast to expand at a compound annual growth rate (CAGR) of 14.4%, reaching USD 11.6 billion by 2033. This significant growth highlights the rising adoption of robotic vacuum cleaners…
Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
The global brain-computer interface (BCI) market was valued at USD 1.6 billion in 2022 and is projected to reach USD 6.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2033. This expansion reflects the increasing adoption of BCI technologies in medical applications, driven by advancements in neuroscience, AI, and sensor technologies. BCIs enable direct communication between the brain and external devices, offering…
Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2 …
The global orally disintegrating tablet (ODT) market is valued at USD 24.45 billion in 2024 and is forecasted to expand at a compound annual growth rate (CAGR) of 11.5%, reaching USD 72.68 billion by 2034. This robust growth is driven by the increasing demand for patient-friendly dosage forms, particularly among the elderly, pediatric, and dysphagic populations, who benefit from ODTs' ease of administration without water and rapid dissolution. ODTs enhance…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
